$CLS

MIONIS ROBERT sold $36.3M of CLS (indirect holdings)

MIONIS ROBERT (Chief Executive Officer) sold 98,453 indirectly-held shares of CELESTICA INC (CLS) at an average of $368.99 ($360.28–$374.16, $36.33M total) across 20 trades on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MIONIS ROBERT
Published Aug 7, 2026, 12:19 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLS
Neutral
medium confidence
Mentioned
$CLS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLSNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around management confidence, but the 10b5-1 structure generally limits inference about near-term business outlook.

02

Market read

A large CEO share sale ($36.3M) is disclosed, but it is pre-arranged under 10b5-1, suggesting a modest and likely short-lived market impact.

03

What to watch

The filing notes indirect holdings and multiple small trades across a price band, which can make the sale less informative than a single, clearly timed discretionary transaction.

Relevance 6/10Novelty 4/10Timing: SEC Form 4 filed Aug 6, covering Aug 4 sales.

Background

The article is an SEC Form 4 insider transaction disclosure for Celestica (CLS) by CEO Mionis Robert, indicating an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CLSNeutralMedium confidence
Context

Celestica CEO Mionis Robert sold $36.3M of CLS shares via a 10b5-1 plan, disclosing 98,453 shares sold at $360.28–$374.16.

Expected impact

Likely limited, short-lived negative bias unless accompanied by other fundamental news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with large dollar value, but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens interpretive impact.

Market effects

Minimal, as this is company-specific insider activity without sector-wide policy or guidance changes.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on fundamentals.

Key entities

  • CELESTICA INC

    Subject of the Form 4 insider transaction disclosure.

  • MIONIS ROBERT

    CEO and officer/director who sold shares via a 10b5-1 plan.

Related articles

$CLSMedAI 8/10

Celestica Completes Equity Offering

Celestica Inc. (NYSE: CLS, TSX: CLS) said it completed its equity offering of 9,677,419 common shares at $310 per share. Including the underwriters’ option, 11,129,031 shares were sold for about $3.45 billion in gross proceeds. Net proceeds will be used for working capital, capital expenditures, and general corporate purposes.

$CLSHighAI 9/10

Celestica Falls After Pricing $3 Bln Equity Offering

Celestica Inc. (CLS) shares fell nearly 12% after the company priced a $3.0 billion public equity offering. According to the company, it sold 9.68 million common shares at $310 each, raising expected gross proceeds of $3.0 billion, and gave underwriters a 30-day option for up to 1.45 million additional shares. CLS traded around $319.48, down about $43.28.

$CLSHighAI 9/10

Why is Celestica stock sliding today?

Celestica (CLS) shares fell 13.7% after the company priced a $3 billion common stock offering at $310 per share, down from the prior close of $362.76. Celestica plans to sell about 9.68 million treasury shares, with underwriters able to buy 1.45 million more. Management said the raise supports AI compute and networking demand.

$CLSMedAI 8/10

Celestica Announces Pricing of Equity Offering

Celestica Inc. (NYSE: CLS, TSX: CLS) priced an equity offering of 9,677,419 common shares at $310 per share. Gross proceeds are expected at about $3.0 billion before underwriting discounts and expenses. Underwriters have a 30-day option to buy up to 1,451,612 additional shares. Net proceeds will fund working capital and capital expenditures, among other purposes. Closing is expected around Aug. 7, 2026.